tiprankstipranks
pc:trell

Trellis Bioscience

A clinical-stage biotechnology company developing native human monoclonal antibodies to treat intractable infectious diseases. Focused on advancing calpurbatug (TRL1068), an investigational monoclonal antibody being evaluated for chronic prosthetic joint infections (PJI).

Leadership & Board

Currently, no data available

Latest Estimated Valuation

Estimated Valuation
Estimated Valuation
Total Amount Raised$9M
Total Amount Raised$9M
Total Funding Rounds1
Total Funding Rounds1
Latest Funding Amount$9M
Latest Funding Amount$9M
Latest Funding RoundSeries C
Latest Funding RoundSeries C
Post-Money Valuation
Post-Money Valuation

Funding Round

Funding Date
Funding Round
Amount Raised
Post-Money Valuation
Jul 16, 2026
Series C
$9.00M

Similar Companies

A snapshot of private companies similar to Trellis Bioscience, helping you discover and navigate related company profiles.

Related News and Analysis